Novo Nordisk (NVO) Stock Overview
Engages in the research and development, manufacture, and distribution of pharmaceutical products. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
NVO Community Fair Values
Create NarrativeSee what 650 others think this stock is worth. Follow their fair value or set your own to get alerts.
Novo Nordisk will thrive with a 34.7751% profit margin boost
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Novo Nordisk A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 47.42 |
| 52 Week High | DKK 93.80 |
| 52 Week Low | DKK 43.08 |
| Beta | 0.40 |
| 1 Month Change | -23.84% |
| 3 Month Change | 5.45% |
| 1 Year Change | -46.16% |
| 3 Year Change | -33.02% |
| 5 Year Change | 33.11% |
| Change since IPO | 26,062.90% |
Recent News & Updates
Recent updates
Novo Nordisk: The Possible Upside
Feb 17Weekly Picks: ASML's Selloff Explained, WH's Global Expansion, and NVO's Market Mispricing
Aug 05
A Quality Compounder Marked Down on Overblown Fears
Policy pressure: US price cuts via the IRA and executive orderNovo Nordisk: Examining Tariff And Pricing Risks
Apr 26Novo Nordisk: A Price Too Low To Ignore
Apr 18Eli Lilly Vs. Novo Nordisk: Which Is The Better Bargain For Investors
Mar 30Novo Nordisk: CagriSema Disappoints Again
Mar 10Why Novo Nordisk Is A Strong Buy Despite Market Concerns
Feb 20Novo Nordisk: Dips Like These Come Once Every Few Years
Feb 13Novo Nordisk aims for a promising future with a fair value of 101.75
Revenue growth is expected to be driven by continued demand for GLP-1 drugs, especially Ozempic and Wegovy.Novo Nordisk Q4 Earnings: Outperformance Suggests Stock Price Comeback Starts Today
Feb 05Novo Nordisk: Excellent Opportunity To Buy The Dip
Jan 15Novo Nordisk Vs. Eli Lilly: Obesity Makes Their Future Bright, But One Of Them Has More Potential
Jan 06Novo Nordisk Stock: A Rare Buying Opportunity
Dec 20Novo Nordisk: Just The Right Price (Rating Upgrade)
Dec 11Novo Nordisk: Can CagriSema Show 25% Weight Loss In REDEFINE-1 Trial?
Nov 25Novo Nordisk: A GLP-1 Leader Faces Increasing Competition
Nov 06Novo Nordisk: A Diabetes Leader Among Big Pharma, But Still Overvalued
Oct 21Multiple Strong Catalysts And Attractive Valuation Make Novo Nordisk A Buy
Sep 18Shareholder Returns
| NVO | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -4.3% | -1.3% | 1.0% |
| 1Y | -46.2% | 25.5% | 14.6% |
Return vs Industry: NVO underperformed the US Pharmaceuticals industry which returned 25.5% over the past year.
Return vs Market: NVO underperformed the US Market which returned 14.6% over the past year.
Price Volatility
| NVO volatility | |
|---|---|
| NVO Average Weekly Movement | 8.5% |
| Pharmaceuticals Industry Average Movement | 9.3% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: NVO has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: NVO's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1923 | 69,150 | Maziar Doustdar | www.novonordisk.com |
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas.
Novo Nordisk A/S Fundamentals Summary
| NVO fundamental statistics | |
|---|---|
| Market cap | US$211.11b |
| Earnings (TTM) | US$16.16b |
| Revenue (TTM) | US$48.76b |
Is NVO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NVO income statement (TTM) | |
|---|---|
| Revenue | DKK 309.06b |
| Cost of Revenue | DKK 54.38b |
| Gross Profit | DKK 254.69b |
| Other Expenses | DKK 152.25b |
| Earnings | DKK 102.43b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
May 06, 2026
| Earnings per share (EPS) | 23.04 |
| Gross Margin | 82.41% |
| Net Profit Margin | 33.14% |
| Debt/Equity Ratio | 63.1% |
How did NVO perform over the long term?
See historical performance and comparisonDividends
Does NVO pay a reliable dividends?
See NVO dividend history and benchmarks| Novo Nordisk dividend dates | |
|---|---|
| Ex Dividend Date | Mar 30 2026 |
| Dividend Pay Date | Apr 08 2026 |
| Days until Ex dividend | 35 days |
| Days until Dividend pay date | 44 days |
Does NVO pay a reliable dividends?
See NVO dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/22 14:49 |
| End of Day Share Price | 2026/02/20 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Novo Nordisk A/S is covered by 53 analysts. 23 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier |
| Gerhard Schwarz | Baader Helvea Equity Research |
| Emily Field | Barclays |